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Abstract
Background: The role of inhaled steroids in patients with chronic respiratory diseases is a matter of debate due to
the potential effect on the development and prognosis of community-acquired pneumonia (CAP). We assessed
whether treatment with inhaled steroids in patients with chronic bronchitis, COPD or asthma and CAP may affect
early outcome of the acute pneumonic episode.
Methods: Over 1-year period, all population-based cases of CAP in patients with chronic bronchitis, COPD or
asthma were registered. Use of inhaled steroids were registered and patients were followed up to 30 days after
diagnosis to assess severity of CAP and clinical course (hospital admission, ICU admission and mortality).
Results: Of 473 patients who fulfilled the selection criteria, inhaled steroids were regularly used by 109 (23%). In the
overall sample, inhaled steroids were associated with a higher risk of hospitalization (OR=1.96, p = 0.002) in the
bivariate analysis, but this effect disappeared after adjusting by other severity-related factors (adjusted OR=1.08,
p=0.787). This effect on hospitalization also disappeared when considering only patients with asthma (OR=1.38,
p=0.542), with COPD alone (OR=4.68, p=0.194), but a protective effect was observed in CB patients (OR=0.15,
p=0.027). Inhaled steroids showed no association with ICU admission, days to clinical recovery and mortality in the
overall sample and in any disease subgroup.
Conclusions: Treatment with inhaled steroids is not a prognostic factor in COPD and asthmatic patients with CAP,
but could prevent hospitalization for CAP in patients with clinical criteria of chronic bronchitis.
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Introduction
Community-acquired pneumonia (CAP) remains an
important cause of morbidity and mortality in industrialised
countries, with a hospitalization rate between 22% and 51%
[1,2] and a lethality rate between 3% and 24% [3,4]. Chronic
bronchitis (CB), chronic obstructive pulmonary disease (COPD)
and asthma are well known risk factors for CAP [4–6]. Some
studies have suggested that treatment with inhaled steroids
may also increase the risk of CAP, the effect of which being
independent of the underlying diseases suffered by these
patients [7,8]. In The TOwards a Revolution in COPD Health
(TORCH) study, there was an increased probability of having
pneumonia reported as an adverse event in patients treated
with inhaled fluticasone propionate either alone or in
combination with salmeterol compared with patients
randomised to salmeterol alone or placebo (7). Further studies
have also shown an association of inhaled steroids therapy and
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the incidence of CAP in COPD patients [8–11]. However,
despite the increase in the frequency of pneumonia observed
with the use of inhaled steroids in chronic pulmonary disease,
there has been no associated rise in mortality reported by any
of the recent trials [7–9,12]. On the contrary, some authors
have shown a reduction of mortality in COPD patients treated
with inhaled steroids [12,13]. This had led to speculation that
the use of inhaled steroids may increase the risk for CAP but
protect against severe pneumonia or pneumonia-related
complications [14,15].
The present study aimed to explore whether treatment with
inhaled steroids in patients with CB, COPD or asthma who
developed CAP may affect the prognosis of the acute
pneumonic episode.
Methods
Design and study population
The Community-Acquired Pneumonia in Catalan Countries
(PACAP) study is a population-based study conducted in an
extensive rural and urban area on the Eastern Coast of Spain,
with predominantly Mediterranean climatic conditions, aimed to
identify risk factors for CAP. Over 1-year period, 1336 incident
cases of CAP from a population of 859,033 inhabitants > 14
years of age were recruited. Details of this study have been
previously published elsewhere [16].
Identification of cases
All suspected cases of CAP occurring in the study population
between November 1999 and November 2000 were registered.
Predefined criteria for case registration were based on acute
lower respiratory tract infection for which antimicrobials had
been prescribed in association with the appearance of
previously unrecorded focal signs on physical examination of
the chest and new radiologic findings suggestive of pulmonary
infiltrate [17]. All cases in which criteria for clinical suspicion
were met were periodically re-evaluated until complete
recovery. Patients in whom the diagnosis was not confirmed
because of clinical evolution and chest radiograph images not
consistent with CAP were excluded as were patients with
aspiration pneumonia, active pulmonary tuberculosis, and
patients coming from nursing homes or having been
discharged from hospital < 7 days before the onset of
symptoms. All public and private medical centres of the study
area as well as reference hospitals outside the area
participated in the reporting of cases.
The present study was restricted to patients with CAP who
were candidates to use inhaled steroids due to the following
baseline chronic respiratory disease: chronic bronchitis, COPD
or asthma. From the original study population of 1,336 cases of
CAP, 473 presented with chronic bronchitis, COPD or asthma.
The study protocol was approved by the Institutional review
board of the Consorci Sanitari del Maresme (Barcelona, Spain)
and all participants gave written informed consent before
enrollment.
Data collection and main outcome measures
At the time of CAP diagnosis, a questionnaire on CAP risk
factors was administered directly to participants by trained
physicians or nurses at home. The questionnaire included
standardised information related to the following three aspects
relating prognosis and severity of CAP: 1) health habits and
lifestyle, 2) chronic respiratory diseases and other clinical
conditions and comorbidity, including the CRB-65 severity
score [18] for the current pneumonic episode, and 3) regular
treatments during the last year. COPD was defined by the
presence of persistent airflow limitation diagnosed by
respiratory function tests documented in the medical records or
stated by the patient. Patients with chronic bronchitis did not
have spirometric study or COPD and were defined by its
arbitrary epidemiological characterization of cough and
expectoration over 90 days per year in two consecutive years
and not secondary to any specific respiratory disease [19].
Asthma was defined by the presence of episodes of validated
clinical symptoms and/or confirmatory medical documentation
of its diagnosis [20]. Treatments were confirmed by medical
records, prescriptions or, when necessary, by direct
observation.
All patients were followed during 30 days after CAP
diagnosis and/or until complete healing or death. Main outcome
variables for CAP included hospital admission, length of
hospital stay, ICU admission, 30-day mortality percentage and
number of days to clinical healing (disappearance of all clinical
symptoms).
Statistical analysis
The bivariate effect of inhaled steroids on hospital admission,
ICU admission and mortality was estimated as odds ratio (OR)
and the 95% confidence interval (CI) by logistic regression
analysis. In addition to the crude bivariate analysis for hospital
admission, a multivariable analysis was performed in which the
effect of inhaled steroids was adjusted by Propensity Score.
The Propensity Score, was calculated by a multivariate logistic
regression for inhaled steroids, with all variables associated
with inhaled steroids in the bivariate analysis, (sex, age,
hospital admission in the last 5 years, home oxygen therapy,
previous radiologically-confirmed pneumonia, oral steroids and
alcohol consumption). This model gives an individual’s
probability of being treated with inhaled steroids given the
complete information about that individual. This probability was
used to adjust the effect of inhaled steroids on hospital
admission. The effect of inhaled steroids on days of hospital
stay and days until clinical recovery/healing was estimated by
the beta coefficient (β) and its 95% CI of the linear regression
model. Finally, survival analysis was performed with the
Kaplan-Meier method. Survival curves for the event of “clinical
healing” for the groups with and without inhaled steroids were
compared with the log-rank test. All these analyses were
performed for the overall sample and for the following
subgroups: patients with asthma alone, patients with CB alone
and patients with COPD alone. Statistical significance was set
at p< 0.05.
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Results
A total of 473 patients with CAP confirmed by clinical
evolution and radiographic findings with history of CB, COPD
or asthma were identified. Sixty percent of patients were men
with a mean age of 62 years and 40% women with a mean age
of 55 years. Use of inhaled steroids was recorded in 109 (23%)
patients. Hospital admission was required in 226 (47.8%)
patients and ICU admission in 19 (4.0%) patients. A total of 10
patients died, with a 30-day mortality percentage of 2.1%.
The association between treatment with inhaled steroids and
the different CAP outcomes for the overall sample and for the
three study groups are shown in Table 1. In the overall sample,
treatment with inhaled steroids was significantly associated
with hospital admission, doubling the estimated risk of
admission in relation to the patients without treatment.
However, there were no significant relationships between
inhaled steroids and ICU admission, 30-day mortality, length of
hospital stay or days to clinical healing. In the Kaplan-Meier
analysis, time to clinical healing of the pneumonic episode for
patients with and without treatment with inhaled steroids was
also similar (log-rank 0.416) (Figure 1). In those patients with
known doses of inhaled steroids (n=55) we observed a dose–
response trend with the risk of hospital admission (OR=4.62 for
using 1-2 puffs/day, OR=8.93; p<0.001). The stratified analysis
by type of respiratory disease showed that patients with clinical
signs or symptoms of CB, inhaled steroids nearly reach a
significant protective effect on CAP hospital admission, and
patients with COPD, had a significant risk for CAP hospital
admission.
The treatment with inhaled steroids had a relationship with
most factors related to prognosis and severity of CAP (Table
2). Hence, the use of inhaled steroids was significantly
associated with age, home oxygen therapy, hospital admission
in the past 5 years, previous pneumonia confirmed by
radiological findings, oral steroids, alcohol consumption, and
CRB-65 score. Most of these factors (age, home oxygen
therapy, hospital admission in the past 5 years, oral steroids)
appeared associated with the need of hospital admission of
patients with CAP, but not for ICU admission nor for 30-day
mortality.
Table 3 shows, for the overall sample and for the three study
groups, the effect of inhaled steroids on hospitalization for CAP
adjusted by Propensity Score. Treatment with inhaled steroids
was not associated with hospitalization for CAP in the overall
sample and in patients with asthma, COPD and COPD with
hiperreactivitat bronquial, but showed a protective effect in
patients with CB. In patients with COPD a strong effect
increasing the risk of hospitalization was observed although it
did not reach the statistical significance. The adjusted effect of
inhaled steroids on ICU admission and mortality continued
being not statistically significant. For continuous outcomes, i.e.
Table 1. Association between treatment with inhaled steroids and main outcomes in patients with CAP.
Outcome variables Use of inhaled steroids Effect estimation p value
 Yes No. (%) No No. (%)   
TOTAL (n = 109) (n = 364)   
Hospital admission 66 (60.0) 160 (44.0) 1.96* (1.27-3.03) 0.002
ICU admission 6 (5.5) 13 (3.6) 1.57* (0.58-4.24) 0.404
Death (30-day mortality) 2 (1.8) 8 (2.2) 0.81* (0.17-3.90) 1.000
Length hospital stay, days, mean ± SD 9.0 ± 4.9 8.9 ± 6.0 0.09† (-1.55-1.73) 0.380
Days to clinical recovery, mean ± SD 14.4 ± 10.9 16.1 ± 12.7 -1.71† (-4.80-1.38) 0.497
ASTHMA (n=22) (n=234)   
Hospital admission 10 (45.5) 78 (33.3) 1.67 (0.69-4.03) 0.252
ICU admission 1 (4.5) 7 (3.0) 1.54 (0.18-13.2) 0.518
Death (30-day mortality) 1 (5.3) 3 (1.5) 3.69 (0.36-37.3) 0.304
Length hospital stay, days, mean ± SD 10.7 (7.1) 8.5 (5.6) 2.16 (-1.71-6.03) 0.368
Days to clinical recovery, mean ± SD 15.1 (11.3) 15.9 (11.7) -0.76 (-7.14-5.62) 0.751
CB (n=12) (n=26)   
Hospital admission 5 (41.7) 20 (76.9) 0.21 (0.05-0.93) 0.064
ICU admission 0 (0) 0 (0) — —
Death (30-day mortality) 0 (2) 2 (8.7) — 1.000
Length hospital stay, days, mean ± SD 8.6 (3.5) 8.7 (5.3) -0.14 (-5.37-5.10) 0.774
Days to clinical recovery, mean ± SD 14.2 (7.7) 14.8 (11.3) -0.54 (-9.00-7.93) 0.667
COPD (n=22) (n=25)   
Hospital admission 21 (95.5) 17 (68.0) 9.88 (1.12-87.0) 0.025
ICU admission 1 (4.5) 0 (0) — 0.468
Death (30-day mortality) 0 (0) 0 (0) — —
Length hospital stay, days, mean ± SD 7.5 (3.7) 8.2 (6.5) -0.66 (-4.11-2.78) 0.939
Days to clinical recovery, mean ± SD 9.4 (7.8) 15.6 (20.2) -6.21 (-16.3-3.88) 0.456
* Odds ratio and 95% confidence interval from logistic regression.
† Regression coefficients and 95% confidence intervals from linear regression.
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number of days of hospital stay and number of dais to clinical
healing, multiple linear regression models neither show a
statistically significant independent effect of inhaled steroids.
Table 2. Association between use of inhaled steroids and
factors related to prognosis and severity of CAP.
 Use of inhaled steroids OR (95% CI) p value
 Yes (n = 109)No (n = 364)   
Sex (% females) 41 (37.6) 148 (40.7) 0.88 (0.57-1.37) 0.569
Age, years, mean ± SD 68.3 ± 17.1 56.9 ± 20.1 1.03 (1.02-1.05) < 0.001
Number of affected lobes >
1
9 (8.9) 33 (9.6) 0.92 (0.43-2.0) 0.837
Home oxygen therapy 15 (14.6) 13 (4.0) 4.14 (1.90-9.03) < 0.001
Hospital admission in the
last 5 years
79 (72.5) 177 (48.6) 2.78 (1.74-4.44) < 0.001
Number hospital
admissions in the last 5
years, mean ± SD
3.6 ± 3.6 2.2 ± 2.8 1.17 (1.05-1.31) < 0.001
Previous radiologically-
confirmed pneumonia
38 (34.9) 75 (20.6) 2.06 (1.29-2.30) 0.002
Number of previous
radiologically-confirmed
CAP, mean ± SD
0.6 ± 1.0 0.3 ± 0.7 1.59 (1.26-2.07) 0.001
Oral steroids 25 (22.9) 10 (2.7) 10.5 (4.87-22.8) < 0.001
Smoking habit (never
smoker)
43 (39.4) 114 (31.3) 1.43 (0.92-2.23) 0.114
Alcohol consumption 3 (2.8) 36 (9.9) 0.26 (0.08-0.85) 0.017
CBR-65 score (moderate/
high risk of death)
28 (44.4) 44 (23.7) 2.58 (1.42-4.71) 0.002
Odds ratio and 95% confidence interval.
Data as absolute numbers and percentages in parenthesis unless otherwise
stated.
Discussion
It has been suggested that treatment with inhaled steroids
may prevent a higher severity of CAP in relation to reduction of
airway inflammation and recruitment of neutrophils, leading to a
blunted systemic inflammatory response [21,22]. Clinically, this
has been analysed in different studies, such as the TORCH
study [7] in which a lower mortality in COPD patients with CAP
previously treated with inhaled steroids was found. This
observation was also reported in the INSPIRE study [12]. In
this study, although there was a greater risk of CAP in the
combined treatment arm (salmeterol and fluticasone) as
compared with tiotropium bromide, the mortality after 2 years
was lower (3% vs. 6%, P < 0.032). In this respect, Malo de
Molina et al. [13] also demonstrated a reduction of 24% in the
30-day mortality rate associated with the use of inhaled steroid
therapy in COPD patients older than 64 years of age admitted
Table 3. Effect of treatment with inhaled steroids on
hospitalization for CAP adjusted by potential confounding
factors.
Hospital admission Effect estimation* p value
TOTAL   
Inhaled steroids 1.08 (0.64-1.81) 0.787
ASTHMA   
Inhaled steroids 1.38 (0.49-3.87) 0.542
CB   
Inhaled steroids 0.15 (0.03-0.80) 0.027
COPD   
Inhaled steroids 4.68 (0.46-47.8) 0.194
* Odds ratio and 95% confidence interval from logistic regression adjusted by
Propensity Score.
Figure 1.  Time to clinical healing according to the use of inhaled steroids in patients with CAP.  
doi: 10.1371/journal.pone.0073271.g001
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to the hospital because of CAP. A lower mortality was not
found in the study of Kardos et al. [9] when salmeterol
monotherapy was compared with combined treatment with
salmeterol and fluticasone in patients with severe COPD; in
this study, combined treatment was associated with a three-
fold increased risk for CAP but differences in mortality were not
observed. Moreover, Singh and co-workers [23] in a meta-
analysis of randomised clinical trials with inhaled steroids as
the intervention drug, have shown an increased risk of CAP
with the use of inhaled steroids although it was not
accompanied by a higher CAP-related mortality or overall
mortality. In the same line, a recent meta-analysis [24] in which
randomised, double-blind clinical trials carried out in patients
with COPD were analysed, showed an increased risk for CAP
associated with the use of inhaled steroids but when the effect
on mortality was assessed, results were not statistically
significant (OR = 0.86, 95% CI 0.68-1.09). Ernst et al. [10]
reported a higher severity of CAP assessed by the need of in-
patient care among patients previously treated with inhaled
steroids, with a direct dose-hospitalization risk relationship.
Moreover, the risk of hospitalization for CAP decreases
progressively after withdrawal of inhaled steroid therapy.
According to these data, inhaled steroids may be related to
other physiopathological mechanisms that may act on the
severity of CAP independently of the reduction of airway
inflammation and the recruitment of neutrophils.
In the presence of this controversy, we here provide the
results of a population-based study with more than half of the
cases being treated in the outpatient setting. Although we
found that on overall the treatment with inhaled steroids was
associated to criteria of severity or worse prognosis, in terms of
hospital admission, after adjusting by other severity-related
factors, the use of inhaled steroids did not show an
independent effect on the prognosis of CAP. Therefore,
treatment with inhaled steroids seems to be a consequence
rather than a cause of severity. However, it is very difficult to
differentiate the severity of CAP from the severity of the
underlying chronic pulmonary diseases because both diseases
are closely linked. Nevertheless, in the group of patients with
CB, but not in patients with COPD or patients with asthma,
inhaled steroids seem to prevent hospitalization for CAP. In
more severe diseases (patients with COPD) the protective
effect of inhaled steroids disappears. The effect of inhaled
steroids is thus modified by the type of underlying chronic
respiratory disease.
The present results, however, should be interpreted taking
into account some limitations of the study. In particular, and
although the large study sample, we observed a small
incidence of outcomes in terms of mortality and ICU admission.
This is in agreement with the clinical course of the CAP [16],
but it could affect the statistical power to detect some effect of
inhaled steroid therapy in these outcomes. In addition, patients
were followed for a short period of time and, therefore, only
immediate prognosis or early outcome of the acute pneumonic
episode was evaluated. Finally, the analyzed data correspond
to patients assessed 12 years ago. During this period
management of inhaled treatments and CAP may have
changed in usual clinical practice.
In summary, this study found no evidence to support the
hypothesis that previous use of inhaled steroids improves
clinical outcomes in CAP patients with asthma or COPD.
However, the use of inhaled steroids has a protective effect on
hospital admission for CAP, but not in other clinical outcomes,
in patients with CB. Our results are in contrast to some existing
studies and, thus, further research is required in this
controversial topic.
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